The University of the Philippines (UP) Manila is currently developing a novel cell-based immunoassay platform for serologic testing for coronavirus disease (COVID-19).
Funded by the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD), the project entitled "Development of a Cell-Based Immunoassay for COVID-19 Serologic Testing" is led by Dr. Fresthel Monica M. Climacosa of UP Manila and collaborators from the University of Toronto, Canada.
"There are actually three types of tests available for COVID-19. We have the Polymerase chain reaction (PRC) testing, we have the antigen testing -- both can test for infection," DOST Secretary Fortunato "Boy" de la Pena said in a taped report.
"On the other hand, serological testing which tests for antibodies against SARS-CoV-2 can detect whether a person has been infected with COVID-19 in the past," he continued.
De la Pena said serological testing is suggested by the World Health Organization to support the diagnosis of COVID-19.
"Some recommends its use to aid in diagnosis of subclinical cases of COVID-19 and to determine to which extent COVID-19 spreads since it can determine how many people may have been infected with COVID-19 in a community or region," he said.
"Serological test also helps determine who qualifies to donate convalescent plasma for the treatment of hospitalized patients with COVID-19," he added.
The cell-based COVID-19 test will be using engineered yeast cells to detect antibodies against SARS-CoV-2 and can be used in remote areas lacking sophisticated laboratory equipment and infrastructure.
The study is expected to end in May 2022 and is seen to benefit communities, researchers, and clinicians in improving access to diagnostic tools for mass disease surveillance.